Literature DB >> 18180147

Potential role of non-antibiotics (helper compounds) in the treatment of multidrug-resistant Gram-negative infections: mechanisms for their direct and indirect activities.

Marta Martins1, Sujata G Dastidar, Seamus Fanning, Jette E Kristiansen, Joseph Molnar, Jean-Marie Pagès, Zsuzsanna Schelz, Gabriella Spengler, Miguel Viveiros, Leonard Amaral.   

Abstract

Multidrug resistance in Gram-negative bacteria is now known to be primarily caused by overexpression of efflux pumps that extrude unrelated antibiotics from the periplasm or cytoplasm of the bacterium prior to their reaching their intended target. This review focuses on a variety of agents that have been shown to be efflux pump inhibitors (EPIs) and which, if used as 'helper compounds' in combination with antibiotics to which the organism is initially resistant, may produce the required cure. Although not all of the EPIs may serve a helper role owing to their toxicity, they may nevertheless serve as lead compounds.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18180147     DOI: 10.1016/j.ijantimicag.2007.10.025

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  35 in total

Review 1.  Efflux-mediated drug resistance in bacteria: an update.

Authors:  Xian-Zhi Li; Hiroshi Nikaido
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

Review 2.  Drug-gut microbiota interactions: implications for neuropharmacology.

Authors:  Jacinta Walsh; Brendan T Griffin; Gerard Clarke; Niall P Hyland
Journal:  Br J Pharmacol       Date:  2018-06-28       Impact factor: 8.739

3.  Random mutagenesis of the multidrug transporter AcrB from Escherichia coli for identification of putative target residues of efflux pump inhibitors.

Authors:  Sabine Schuster; Samay Kohler; Annika Buck; Christine Dambacher; Armin König; Jürgen A Bohnert; Winfried V Kern
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

4.  Experimental analyses of synergistic combinations of antibiotics with a recently recognised antibacterial agent, lacidipine.

Authors:  A Dasgupta; S Chaki; S Mukherjee; J Lourduraja; K Mazumdar; N K Dutta; S G Dastidar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-12-13       Impact factor: 3.267

5.  In vitro and in vivo efficacies of amlodipine against Listeria monocytogenes.

Authors:  N K Dutta; K Mazumdar; A DasGupta; S G Dastidar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-01-28       Impact factor: 3.267

6.  A Mycobacterium tuberculosis sigma factor network responds to cell-envelope damage by the promising anti-mycobacterial thioridazine.

Authors:  Noton K Dutta; Smriti Mehra; Deepak Kaushal
Journal:  PLoS One       Date:  2010-04-08       Impact factor: 3.240

Review 7.  The anti-inflammatory non-antibiotic helper compound diclofenac: an antibacterial drug target.

Authors:  K Mazumdar; S G Dastidar; J H Park; N K Dutta
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-04-28       Impact factor: 3.267

Review 8.  Bacterial-Host Interactions: Physiology and Pathophysiology of Respiratory Infection.

Authors:  A P Hakansson; C J Orihuela; D Bogaert
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

9.  A Simple Method for Assessment of MDR Bacteria for Over-Expressed Efflux Pumps.

Authors:  Marta Martins; Matthew P McCusker; Miguel Viveiros; Isabel Couto; Séamus Fanning; Jean-Marie Pagès; Leonard Amaral
Journal:  Open Microbiol J       Date:  2013-03-22

10.  Pimozide Inhibits the AcrAB-TolC Efflux Pump in Escherichia coli.

Authors:  Jürgen A Bohnert; Sabine Schuster; Winfried V Kern
Journal:  Open Microbiol J       Date:  2013-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.